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ABSTRACT
Objective: To provide reference values for the French version of the
EQ-5D and verify its capacity to discriminate between subgroups.
Methods: General population mail survey in French-speaking Switzerland
that included the EQ-5D instrument (ﬁve items rated on three levels as no
problem, moderate problem, severe problem, and a visual analog health
scale between 0 and 100) and descriptive variables.
Results: Questionnaires were returned by 1956 adults (response rate
52.1%). Three of the ﬁve items had important “ceiling” effects (proportions
with no problem:mobility 92.1%, self-care 97.6%, usual activities 91.2%),
the other two less so (pain/discomfort 54.3%, anxiety/depression 68.1%).
Four health states represented the majority of the population: no health
problem (41.8%), moderate pain/discomfort only (21.0%), moderate
anxiety/depression only (11.5%), moderate pain/discomfort and moderate
anxiety/depression only (13.2%). The mean health utility was 0.83 (SD
0.15) on a scale between 0 and 1 and the mean visual analog score 81.7 (SD
15.5); the two were correlated (Pearson r 0.63, P < 0.001). Health utility
scores were lower among women, older respondents, those with basic
education, users of health services, and those with lower self-reported
health status. The patternwas similar for the visual analog score except that
women reported slightly higher ratings than men.
Conclusion: The EQ-5D performed as expected in a French-speaking
general population sample. Reference values by sex and age group may
facilitate the interpretation of results obtained in clinical settings.
Keywords: EQ-5D, health utility, population norms.
The EuroQol EQ-5D is frequently used to measure health utility
in medical and public health research. This questionnaire consists
of ﬁve items (regarding mobility, self-care, usual activities, pain
and discomfort, and anxiety or depression), each rated on a
three-point scale (no problem, moderate problem, severe
problem), followed by a 0 to 100 visual analog scale (VAS)
presented as a “thermometer” to assess the global level of health.
The ﬁve items are combined into a single health utility value
using a uniﬁed scoring algorithm that was derived based on time
trade-off data from several European studies [1–4]. The instru-
ment has been translated into numerous languages [5], including
French, but to date no reference data have been published for the
French-language version.
Population-based reference values are useful for the interpre-
tation of any health status measurements [6]. Without reference
values, only health utilities of 1 (perfect health) and 0 (death)
have clear meaning. Average values in a general population (often
stratiﬁed by sex and age group) provide a third meaningful
anchor. Such reference values can be used in assessing the utility
loss of speciﬁc health states and in interpreting change, whether
spontaneous or induced by treatment. For example, if a person’s
health utility has improved from 0.6 to 0.7, it is one quarter of
the distance to perfect health, but perfect health may be an
unattainable goal; if average health utility is known to be 0.8, a
change from 0.6 to 0.7 represents half the distance. The latter
interpretation may be more relevant.
In this article we provide reference scores for the EQ-5D from
a general population setting in French-speaking Switzerland and
describe associations between health utility scores and various
characteristics of the respondents.
Methods
We conducted a mail survey in the general population of French-
speaking Switzerland. All noninstitutionalized residents aged 18
and over were eligible. The study was approved by the research
ethics committee at University Hospitals of Geneva.
The following variables were measured: the ﬁve items and the
VAS of the EQ-5D, current health status compared with the past
6 months’ average (better, same, worse), current health status on
a ﬁve-point scale between poor and excellent, current treatment
for a chronic or acute health problem (separate items), doctor
visit in the past 6 months with a generalist physician, a specialist
(except psychiatrist), a psychiatrist, a psychologist (all of these
dichotomized as none vs. one or more), hospital stay in the past
6 months, sex, age, country of birth (Switzerland, other Euro-
pean country, non-European country), and highest education.
Data collection was conducted in 2007 by an independent
survey ﬁrm that had access to lists of addresses of all legal
residents (Infometrics, Le Muids, Switzerland). The ﬁrm selected
the random sample and mailed the survey packages (cover letter
signed by the investigators, questionnaire, return envelope), col-
lected the numbered returned questionnaires, sent out reminder
packages (up to two reminders to nonrespondents), performed
data entry, and transmitted the data ﬁle to the investigators.
The target sample size was 1645 respondents to allow the
detection of an effect size of 0.2 (i.e., a difference between means
of 0.2 SDs) between clinically meaningful subgroups with 90%
power and 5% type 1 error. We wanted to be able to compare
unequal groups, up to 20% versus 80% of the total sample. For
this situation, the required sample size was 1645 (329 vs. 1316).
Expecting 10% of invalid addresses and a response rate of 45%,
a simple random sample of 4000 individuals was initially
contacted.
We examined the distributions of the EQ-5D items and VAS
scale, computed the health utility for each respondent using the
standard European tariff [3, and table 8.11, p. 124 in 4], expressed
on a scale between 0 and 1, and examined the frequencies of the
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most common health states among the 243 (35) possible permu-
tations. Then, we examined the following dependent variables
across respondent characteristics: proportions with a problem
(moderate or severe) for each of the ﬁve EQ-5D items, proportion
in perfect health (no problem with any of the ﬁve items), mean
health utility, and mean VAS. We used cross tabulation and
chi-square tests for dichotomous outcomes, and T-tests for con-
tinuous outcomes. To assess whether the health utility measure
suffers from a ceiling effect in this general population, we exam-
ined the distributions of various health indicators among the
subset with the highest achievable utility (0.98). Finally, we
reported the observedmeans and SDs of the health utility and VAS
across age-sex strata, as well as expected means obtained from a
linear regression model where outcomes were predicted by sex,
age, and age squared (to capture a possible nonlinear association
with age). The latter equations allow the computation of indi-
vidual expected values without the problems posed by small
samples within strata and by discrete jumps between strata.
Analyses were performed using SPSS software (SPSS Inc, Chicago,
IL).
Results
Of the initial sample 253 persons had invalid addresses, and
1952 of 3747 returned the questionnaire (52.1%). The response
rate was higher among women than among men (56.5% vs.
46.7%, P < 0.001).
Item completion rates ranged from 99.1% (pain/discomfort)
to 99.6% (mobility), and most respondents answered all ﬁve
EQ-5D items (1907, 97.7%). Three of the items had important
ceiling effects (i.e., proportions with a “no problem” assessment),
but anxiety/depression and pain/discomfort revealed substantial
proportions of problems (Table 1). All items displayed a strong
and gradual relationship with the VAS ratings.
Of the 243 possible health states, 51 were observed at least
once, and 21 states were selected by only one respondent each.
Four states represented the majority (87.5%) of the sample
(Table 2): no health problem (41.8%), moderate pain/discomfort
only (21.0%), moderate anxiety/depression only (11.5%), mod-
erate pain/discomfort and moderate anxiety/depression only
(13.2%). The mean health utility was 0.83 on a scale from 0 to
1 (SD 0.15; quartiles 0.76, 0.79, 0.98; range 0.07–0.98). The
mean VAS rating was 81.7 (SD 15.5; quartiles 75, 85, 90; range
0–100). The health utility and VAS were correlated (Pearson r
0.63, P < 0.001).
Men reported more mobility problems than women, but
women reported considerably more anxiety or depression, and
fewer achieved the highest utility level (Table 3). The mean utility
was higher for men. Strong age gradients were seen for all
outcome variables but anxiety/depression. Differences were small
according to the country of birth. Respondents who received
only basic education reported more problems and lower utility
and VAS ratings than other subgroups. Those with a doctor visit
in the past 6 months reported more problems and had lower
scores than their counterparts. Similar results were seen for those
with a mental health visit (psychiatrist or psychologist); never-
theless, a large proportion of the respondents skipped questions
about mental health specialists, and the results for this subgroup
fell in between those of users and nonusers. Equally predictable
patterns were observed for respondents who were hospitalized in
the past 6 months and for those who were treated for a chronic
or an acute health problem. Finally, associations between self-
perceived health status and EQ-5D variables displayed strong
gradients, and the report of worsening health was also strongly
associated with unfavorable outcomes.
We conducted two post hoc analyses. The ﬁrst explored the
variability in health among the 798 respondents with the highest
health utility (no problems on any of the ﬁve items). In this
subgroup, 15.8% reported that they suffered from a chronic
health problem, and 4.7% from an acute health problem. Almost
half (44.4%) had seen a doctor in the past 6 months, and 4.2%
had been hospitalized during that time. They described their
current health status as excellent (23.8%), very good (54.2%),
good (21.7%), or fair (0.3%). Their VAS ratings ranged from 49
to 100, with a mean of 89.5 (SD 9.1), and quartiles of 85, 90, and
96, and 21.4% had VAS values below the population mean of
81.7.
The second post-hoc analysis examined the reasons for a
higher VAS rating among women despite lower health utility. The
unadjusted difference in means between women and men was 1.2
VAS units, not quite statistically signiﬁcant (P = 0.07) (Table 3).
Table 1 Distributions of the 5 EQ-5D items among adult residents of
French-speaking Switzerland, and association with visual analog health
scale
N (%) Mean VAS (SD)
Mobility (7 missing)
I have no problems in walking about 1792 (92.1) 83.8 (13.1)
I have some problems in walking about 150 (7.7) 57.6 (19.9)
I am conﬁned to bed 3 (0.1) 25.0 (15.0)
Self-care (8 missing)
I have no problems with self-care 1897 (97.6) 82.7 (14.2)
I have some problems washing or dressing
myself
39 (2.0) 45.7 (19.4)
I am unable to wash or dress myself 7 (0.4) 36.4 (14.4)
Usual activities (11 missing)
I have no problems with performing my
usual activities
1771 (91.2) 84.3 (12.4)
I have some problems with performing my
usual activities
162 (8.3) 55.3 (18.1)
I am unable to perform my usual activities 7 (0.4) 41.3 (24.8)
Pain/discomfort (15 missing)
I have no pain or discomfort 1050 (54.3) 88.1 (10.4)
I have moderate pain or discomfort 848 (43.8) 75.5 (15.7)
I have extreme pain or discomfort 36 (1.9) 43.7 (20.6)
Anxiety/depression (15 missing)
I am not anxious or depressed 1318 (68.1) 85.2 (12.7)
I am moderately anxious or depressed 572 (29.6) 76.4 (16.4)
I am extremely anxious or depressed 45 (2.3) 49.3 (18.7)
VAS, visual analog scale.
Table 2 Most frequent EQ-5D health states and distributions of corre-
sponding VAS values among 1907 Swiss respondents
Health state
pattern* N (%)
Health
utility VAS (SD)
11111 798 (41.8) 0.98 89.5 (9.0)
11112 219 (11.5) 0.79 84.3 (10.9)
11121 401 (21.0) 0.78 81.2 (12.3)
11122 251 (13.2) 0.70 77.3 (12.0)
11123 9 (0.5) 0.47 57.8 (18.4)
11221 19 (1.0) 0.76 67.6 (14.5)
11222 27 (1.4) 0.68 61.9 (15.3)
11223 9 (0.5) 0.45 53.8 (13.6)
21121 29 (1.5) 0.72 74.0 (11.7)
21122 15 (0.8) 0.65 59.6 (15.3)
21221 24 (1.2) 0.70 61.9 (15.7)
21222 22 (1.1) 0.62 56.8 (15.4)
22222 9 (0.5) 0.52 39.4 (15.1)
Other 75 (3.9) — —
*The digits represent scores for mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression (1 = no problem, 2 =moderate problem, 3 = serious problem).
VAS, visual analog scale.
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After adjustment for health utility, the difference grew to 1.9 and
became statistically signiﬁcant (P = 0.001). Further adjustment
for acute or chronic health problems and for medical visits and
hospitalizations indicated a difference of 2.0 VAS points
(P < 0.001) in favor of women.
Finally, the observed mean values and SDs for the health
utility score and the VAS stratiﬁed by age and sex are shown in
Table 4, as well as smoother predicted scores. The prediction
equation for health utility was 0.84822 - 0.00208 ¥ (age - 50)
- 0.00002 ¥ (age - 50)2 - 0.02090 if female. The prediction
equation for VAS rating was 83.183 - 0.199 ¥ (age - 50)
- 0.006 ¥ (age - 50)2 + 0.401 if female. The effect of age was
statistically signiﬁcant in both equations, the effect of sex was
signiﬁcant only for health utility, and the effect of age squared
was signiﬁcant only for the VAS rating.
Discussion
A French language version of the EQ-5D has been available for
several years [5], but reference values from the general popula-
tion have been lacking. This study ﬁlls this void. We also provide
simple equations based on age and sex that allow the computa-
tion of an expected health utility and an expected VAS rating
from these demographic characteristics. These tools should facili-
tate the interpretation of EQ-5D results obtained in French-
speaking patient groups or populations [6] and encourage a more
widespread use of the instrument.
Overall, the performance of the French EQ-5D and the epi-
demiology of health utility captured by this instrument resembled
those of other published versions. Like others [7–10], we have
observed important ceiling effects for several items, particularly
self-care, but less so for pain/discomfort or anxiety/depression. In
our sample, problems with mobility, self-care, and usual activities
appeared to be less prevalent than in several other populations
[11–14]. Possibly the French translation of “I have some prob-
lems . . .” as “J’ai des problèmes . . .” contributed to this;
although the translation is technically correct, the English phrase
would allow that problems may not always be present, whereas
the French phrase pretty much afﬁrms that problems are always
there. The distribution of health utility values was more evenly
spread out; still, more than 4 out of 10 respondents provided the
highest health rating. This, too, is similar to observations from
other population surveys [7,12,13,15]. The health states of those
who obtained the highest utility rating were not uniformly excel-
lent: e.g., the SD on the VAS rating was 9.1 in this subgroup, less
than 15.5 among all respondents, but still far from zero. This
suggests that the instrument does not capture fully the true
variability in health states at the high end of the spectrum.
The health utility and VAS rating were correlated at 0.63,
close to what was observed in Canada [15], Greece [13], Spain
[16], and the UK [17]. This conﬁrms that self-perceived health is
related but not identical to health utility assessed by means of the
ﬁve domain-speciﬁc items. This distinction is also illustrated by
the opposite direction of sex differences for the health utility and
the VAS. Women had on average lower health utility scores than
men, predominantly because of a higher prevalence of anxiety
and depression, but slightly higher values of self-perceived health
on the thermometer scale. The sex difference in VAS ratings was
strengthened by adjustment for the EQ-5D health utility, for the
existence of an acute or chronic health problem, and for use of
health services. This suggests that the VAS item may be inter-
preted differently by men and women. Sex differences in the
interpretation of survey items are reported on occasion [18–20].
For instance, in a previous study conducted among university
students, women were more likely to report feeling happy than
men after adjustment for relevant confounders, including mental
health, the strongest correlate of happiness in that sample [20].
The age-related increase in health problems is also an oft-
reported pattern [8,13,21]. Although we and others [7–9,15]
found that anxiety/depression did not increase with age, at least
one study, from Greece, observed an age-gradient for anxiety/
depression as well [13]. Others too have seen a greater prevalence
of health problems and a lower health utility in the least educated
respondents [8,9,13,22] and among users of health services
[8,9,22]. Finally, the steep gradient in health utility across self-
perceived health status, described on a scale between excellent
and poor, has also been described previously [8,9,16]. Globally,
these similarities suggest that the French translation of the ques-
tionnaire, combined with the use of the European tariff, performs
as expected in a general population.
One limitation of this study is that we did not attempt to
revalidate in French the EQ-5D through preference-based mea-
surements of health utility. Such studies require all participants to
have good cognitive abilities, and all must be willing to engage in
a preference-based utility assessment, which is unrealistic in a
population-based survey such as ours. Previous studies have
found differences in valuations obtained in Finland versus the
United States [23], the UK versus the United States [24], and The
Netherlands versus the UK [25]. Nevertheless, whether local or
universal valuations are preferable is not entirely an empirical
question. Rather, the issue is whether health utilities have univer-
sal meaning or not—or, to be precise, whether health utilities are
universal enough to justify the aggregation of individual utilities
across patient groups or population subsets. The standard Euro-
pean tariff [3,4] may be suboptimal in any local context, but
using a single currency allows comparisons across countries as
well as aggregation of scores obtained in diverse countries, a
necessity for international multicenter clinical trials.
Another limitation of our study is the moderate response
rate of the survey, near 50%. Suboptimal participation is a
Table 4 Reference means and SDs from a general population sample
Age group
EQ-5D health utility Visual analog scale
Women Men Women Men
Observed Predicted* Observed Predicted* Observed Predicted* Observed Predicted*
18–29 0.86 (0.14) 0.87 0.90 (0.11) 0.89 82.8 (12.5) 85.0 85.6 (17.0) 84.6
30–39 0.86 (0.14) 0.86 0.87 (0.12) 0.88 86.6 (12.0) 85.3 85.0 (10.5) 84.8
40–49 0.84 (0.14) 0.84 0.85 (0.16) 0.86 84.0 (15.6) 84.5 82.2 (15.4) 84.0
50–59 0.81 (0.14) 0.82 0.83 (0.15) 0.84 81.6 (14.6) 82.5 82.9 (14.9) 82.1
60–69 0.80 (0.14) 0.80 0.83 (0.14) 0.82 80.2 (15.6) 79.7 80.2 (15.0) 79.3
70–79 0.76 (0.17) 0.77 0.80 (0.14) 0.79 74.7 (17.8) 75.5 73.9 (17.0) 74.7
80 and over 0.74 (0.19) 0.74 0.76 (0.18) 0.76 72.6 (19.3) 69.7 69.0 (21.4) 69.6
*Linear function of sex, age, and age squared.
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feature of many similar general population studies, including
other studies that used the EQ-5D. Nevertheless, the importance
of the resulting selection bias is unknown. Including the EQ-5D
in census surveys or other government-sponsored health
surveys, which typically achieve high response rates, may offer
the best opportunity to estimate the importance of this bias.
Also, this study was conducted in French-speaking Switzerland,
which may limit its applicability to other French-speaking popu-
lations. The generalizability of the predictive equations for
health utility is also unknown; their validation in a new sample
would be desirable.
These results suggest that the French-language version of the
EQ-5D instrument performs as expected. The population norms
that are provided should facilitate the interpretation of EQ-5D
utilities obtained among French-speaking patients.
Source of ﬁnancial support: Research and development grant, University
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Switzerland.
References
1 Brooks R, EuroQoL Group. EuroQoL: the current state of play.
Health Policy 1996;37:53–72.
2 Rabin R, De Charro F. EQ-5D: a measure of health status from
the EuroQoL Group. Ann Med 2001;33:337–43.
3 Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single Euro-
pean currency for EQ-5D health states. Results from a six country
study. Eur J Health Econ 2003;4:222–31.
4 Brooks R, Rabin R, De Charro F. The Measurement and Valua-
tion of Health Status Using EQ-5D: A European Perspective.
Dordrecht: Kluwer Academic Publishers, 2003.
5 Anonymous. EQ-5D available versions. Available from: http://
www.euroqol.org/eq-5d/eq-5d-versions/eq-5d-languages/
available-versions.html [Accessed on July 16, 2009].
6 Fayers PM, Machin D. Quality of Life—Assessment, Analysis and
Interpretation (Chapter 16.4, Population norms). Chichester:
John Wiley & Sons, 2000.
7 Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an
adult US sample. Qual Life Res 1998;7:155–66.
8 Burström K, Johannesson M, Diderichsen F. Swedish population
health-related quality of life results using the EQ-5D. Qual Life
Res 2001;10:621–35.
9 Wang H, Kindig DA, Mullahy J. Variation in Chinese population
health related quality of life: results from a EuroQol study in
Beijing, China. Qual Life Res 2005;14:119–32.
10 Nordlund A, Ekberg K, Kristenson M, Linquest Group. EQ-5D in
a general population survey—a description of the most commonly
reported EQ-5D health states using the SF-36. Qual Life Res
2005;14:1099–109.
11 Hughes DA. Feasibility, validity and reliability of the Welsh
version of the EQ-5D health status questionnaire. Qual Life Res
2007;16:1419–23.
12 Bharmal M, Thomas J. Comparing the EQ-5D and the SF-6d
descriptive systems to assess their ceiling effects in the US general
population. Value Health 2006;9:262–71.
13 Kontodimopoulos N, Pappa E, Niakas D, et al. Validity of the
EuroQol (EQ-5D) instrument in a Greek general population.
Value Health 2008;11:1162–9.
14 Zarate V, Kind P, Chuang LH. Hispanic valuation of the EQ-5D
health states: a social value set for Latin Americans. Value Health
2008;11:1170–7.
15 Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12
health surveys in a general population survey in Alberta, Canada.
Med Care 2000;38:115–21.
16 Badia Llach X, Herdman M, Schiafﬁno A. Determining corre-
spondence between scores on the EQ-5D “thermometer” and a
5-point categorical rating scale. Med Care 1999;37:671–7.
17 Whynes DK, TOMBOLA Group. Correspondence between
EQ-5D health state classiﬁcations and EQ VAS scores. Health
Qual Life Outcomes 2008;6:94.
18 Shea TL, Tennant A, Pallant JF. Rasch model analysis of the
Depression, Anxiety and Stress Scales (DASS). BMC Psychiatry
2009;9:21.
19 Kendel F, Wirtz M, Dunkel A, et al. Screening for depression:
rasch analysis of the dimensional structure of the PHQ-9 and the
HADS-D. J Affect Disord 2010;122:241–6.
20 Perneger TV, Hudelson PM, Bovier PA. Health and happiness in
young Swiss adults. Qual Life Res 2004;13:171–8.
21 Franks P, Lubetkin EI, Gold MR, et al. Mapping the SF-12 to the
EuroQol EQ-5D index in a national US sample. Med Decis
Making 2004;24:247–54.
22 Lubetkin EI, Jia H, Franks P, Gold MR. Relationship among
sociodemographic factors, clinical conditions and health-related
quality of life: examining the EQ-5D in the US general popula-
tion. Qual Life Res 2005;14:2187–96.
23 Johnson JA, Ohinmaa A, Murti B, et al. Comparison of Finnish
and US-based visual analog scale valuations of the EQ-5D
measure. Med Decis Making 2000;20:281–9.
24 Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health
states. Are the United States and United Kingdom different? Med
Care 2005;43:221–8.
25 Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff:
results and arguments for an effective design for national EQ-5D
valuation studies. Health Econ 2006;15:1121–32.
French Version of the EQ-5D 635
